Executive Medical Director
Board Certified in General & Adult Psychiatry
Board Certified in Addiction Medicine
Member, American Psychiatric Association
Member, American Society for Functional Neuroradiology
Michael Mamoun, M.D. is a physician who is board-certified in psychiatry by the American Board of Psychiatry and Neurology, and also board-certified in Addiction Medicine by the American Board of Addiction Medicine. Doctor Mamoun completed his residency training at the Neuropsychiatric Institute of the UCLA Medical Center. UCLA is consistently ranked in the top #1-5 institutions for psychiatry training internationally and in the United States. In addition to his clinical practice, Dr Mamoun is also actively involved in brain imaging and nicotine research.
Dr. Mamoun is experienced in treating the entire spectrum of mental health conditions (including depression, anxiety, bipolar disorder, and ADHD). He is also skilled in treating substance abuse disorders (ranging from nicotine addiction to prescription drug use to recreational drugs). Dr. Mamoun has treated a wide range of patients in multiple settings, including private practice, university medical centers, non-profit clinics, and community hospitals. He has previously served as the Director of Psychiatric Services at Homeless Healthcare Los Angeles and has volunteered at the non-profit Venice Family Clinic. Originally from Chicago, Dr. Mamoun attended college and medical school at the University of Illinois. He then attended the prestigious UCLA Neuropsychiatric Institute for his residency training.
Doctor Mamoun has been involved in medical research for almost twenty years. He has perfomed neuroimaging brain research dating all the way back to his undergraduate years. While there, he researched human memory systems under Dr. Neal Cohen (Beckman Institute), whose lab studied the patient “H.M.” (Link to more info) H.M. is widely regarded as the best-known patient in the history of neuroscience.
More recently, Dr. Mamoun’s research has focused on nicotine addiction and tobacco dependence through the Brentwood Biomedical Research Institute in affiliation with the UCLA and VA Medical Centers. His research projects utilize brain imaging in order to better understand the nature of psychiatric conditions and drug addictions. One such study, recently published in JAMA (Journal of American Medical Association) Psychiatry (Link), showed how functional neuroimaging can be used to help predict future response to smoking cessation. It has since been cited in numerous studies and conferences.
Dr. Mamoun has a unique background in medical technology as well as research and clinical practice. In addition to traditional psychiatric techniques (e.g. psychiatric assessment, neurocognitive assessment), when appropriate he sometimes incorporates modern technological tools in order to assist in his diagnosis and therapy. This includes utilizing pharmaco-genetic testing, and sophisticated neuroimaging. His experience in neuroimaging includes: CT, PET, MRI, DTI, MRS, and fMRI / functional MRI (3D MPRage, Resting BOLD, ASL). He is one of the first psychiatrists in the country to collaborate with fellow behavioral neurologists and neuroradiologists in offering neuroimaging-assisted fMRI-guided TMS (magnetic stimulation of the brain) in order to treat psychiatric conditions in a totally novel way. He is also investigating several emerging technologies for smoking cessation.
Recently published research studies:
Effect of Cigarette Smoking on a Marker for Neuroinflammation: A [11C]DAA1106 PET Study
Journal of Neuropsychopharmacology
Nicotinic acetylcholine receptor availability in cigarette smokers: effect of heavy caffeine or marijuana use.
Journal of Psychopharmacology
Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date
Journal of CNS Drugs
Radiation dosimetry and biodistribution of the translocator protein radiotracer [(11)C]DAA1106 determined with PET/CT in healthy human volunteers.
Journal of Nuclear Medicine and Biology
Brain Nicotinic Acetylcholine Receptor Availability and Response to Smoking Cessation Treatment: A Randomized Trial.
JAMA (Journal of the American Medical Association) Psychiatry. MRI & PET brain imaging study.
Treatment for tobacco dependence: effect on brain nicotinic acetylcholine receptor density.
Neuropsychopharmacology. 2013 Jul;38(8):1548-56. PET neuroimaging study.
Up-regulation of nicotinic acetylcholine receptors in menthol cigarette smokers
International Journal of Neuropsychopharmacology. 2013 Jun;16(5):957-66. PET neuroimaging study.